| Date:2021.10.9 |
|---|
| Your Name:Jian Zhang |
| Manuscript Title:Bioinformatics analysis and experimental verification identifying FBXO45 gene as a |
| potential oncogene in esophageal cancer |
| Manuscript number (if known): |
| , |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| 3 | Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses | None None None | 36 months |
| 4 | Consulting fees | None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
|----|--|-------------------------------|--------------|
| 6 | Payment for expert testimony | None | |
| 7 | Support for attending meetings and/or travel | None | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data | None | |
| | Safety Monitoring Board or Advisory Board | | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | |
| 11 | Stock or stock options | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | |
| 13 | Other financial or non- financial interests | None | |
| | ease summarize the above co | onflict of interest in the fo | llowing box: |

as a

| Dat | te:2021.10.9 | | |
|-----------------------------|---|---|--|
| Υοι | ur Name:Yiping Zhou | | |
| po | nuscript Title:Bioinfo tential oncogene in esoph nuscript number (if known) | nageal cancer | |
| rela par to t rela | ated to the content of your ries whose interests may be transparency and does not ationship/activity/interest, | manuscript. "Related" me e affected by the content on necessarily indicate a bias it is preferable that you do | Il relationships/activities/interests listed below that are cans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment. If you are in doubt about whether to list a o so. ips/activities/interests as they relate to the current |
| | nuscript only. | | <u> </u> |
| to t me | the epidemiology of hypertodication, even if that medic | ension, you should declare ation is not mentioned in pport for the work reporte | defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. ed in this manuscript without time limit. For all other items, |
| | | Name all entities with | Specifications/Comments |
| | | whom you have this relationship or indicate none (add rows as needed) | (e.g., if payments were made to you or to your institution) |
| | | Time frame: Since the initia | al planning of the work |
| | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: pas | t 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | None | |
| ļ | Consulting fees | None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
|----|--|-------------------------------|--------------|
| 6 | Payment for expert testimony | None | |
| 7 | Support for attending meetings and/or travel | None | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data | None | |
| | Safety Monitoring Board or Advisory Board | | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | |
| 11 | Stock or stock options | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | |
| 13 | Other financial or non- financial interests | None | |
| | ease summarize the above co | onflict of interest in the fo | llowing box: |

| Da | te:2021.10.9 | | |
|------------------------------|---|---|--|
| | ur Name:Bo Zhang | | |
| | | - | xperimental verification identifying FBXO45 gene as a |
| po | tential oncogene in esoph | nageal cancer | |
| Ma | anuscript number (if known) | : | |
| rel pa to rel Th | ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, | manuscript. "Related" mea e affected by the content on necessarily indicate a bias. it is preferable that you do | relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so. ps/activities/interests as they relate to the current |
| <u></u> | andscript omy. | | |
| to | • | ension, you should declare | <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. |
| | item #1 below, report all su e time frame for disclosure i | | d in this manuscript without time limit. For all other items, |
| ••• | o time mame for albaroare. | o the past so months. | |
| | . | . | |
| | | Name all entities with | Specifications/Comments |
| | | whom you have this | (e.g., if payments were made to you or to your |
| | | relationship or indicate none (add rows as | institution) |
| | | needed) | |
| | | Time frame: Since the initia | planning of the work |
| 1 | All support for the present | None | |
| _ | manuscript (e.g., funding, | | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | None | |
| | any entity (if not indicated | | |
| 2 | in item #1 above). | N | |
| 3 | Royalties or licenses | None | |
| | | | |
| 4 | Consulting fees | None | |
| - | Consuming ices | | <u> </u> |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
|----|--|-------------------------------|--------------|
| 6 | Payment for expert testimony | None | |
| 7 | Support for attending meetings and/or travel | None | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data | None | |
| | Safety Monitoring Board or Advisory Board | | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | |
| 11 | Stock or stock options | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | |
| 13 | Other financial or non- financial interests | None | |
| | ease summarize the above co | onflict of interest in the fo | llowing box: |

| Da | te:2021.10.9 | | |
|-----------|---|---|---|
| | ur Name:_Chunguo Wang | | |
| Μa | nuscript Title:Bioinf | ormatics analysis and e | experimental verification identifying FBXO45 gene as a |
| | tential oncogene in esoph | | |
| _ | nuscript number (if known) | _ | |
| relator | ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, e following questions apply | manuscript. "Related" me e affected by the content on necessarily indicate a bias it is preferable that you do | Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so. ips/activities/interests as they relate to the current |
| <u>ma</u> | nuscript only. | | |
| to me | the epidemiology of hypertodication, even if that medic | ension, you should declare cation is not mentioned in pport for the work reporte | e defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. ed in this manuscript without time limit. For all other items, |
| | | Name all entities with | Specifications/Comments |
| | | whom you have this relationship or indicate none (add rows as needed) | (e.g., if payments were made to you or to your institution) |
| | | Time frame: Since the initia | al planning of the work |
| | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: pas | t 36 months |
| - | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| } | Royalties or licenses | None | |
| ı | Consulting fees | None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
|----|--|-------------------------------|--------------|
| 6 | Payment for expert testimony | None | |
| 7 | Support for attending meetings and/or travel | None | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data | None | |
| | Safety Monitoring Board or Advisory Board | | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | |
| 11 | Stock or stock options | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | |
| 13 | Other financial or non- financial interests | None | |
| | ease summarize the above co | onflict of interest in the fo | llowing box: |

as a

| Da | te:2021.10.9 | | |
|------------------------|--|---|---|
| Yo | ur Name:Baofu Chen | | |
| | nuscript Title:Bioinf tential oncogene in esopl | | experimental verification identifying FBXO45 gene as |
| _ | anuscript number (if known | _ | |
| rel pa to rel | ated to the content of your rties whose interests may b transparency and does not ationship/activity/interest, | manuscript. "Related" me e affected by the content necessarily indicate a bias it is preferable that you d | |
| | e following questions apply anuscript only. | to the author's relationsh | nips/activities/interests as they relate to the current |
| to me | the epidemiology of hypert edication, even if that medic | ension, you should declar cation is not mentioned in port for the work report | e defined broadly. For example, if your manuscript pertains to all relationships with manufacturers of antihypertensive the manuscript. ed in this manuscript without time limit. For all other items, |
| | | Name all entities with | Specifications/Comments |
| | | whom you have this relationship or indicate | (e.g., if payments were made to you or to your institution) |
| | | none (add rows as needed) | |
| | | Time frame: Since the initi | al planning of the work |
| L | All support for the present manuscript (e.g., funding, provision of study materials, | None | |
| | medical writing, article processing charges, etc.) No time limit for this item. | | |
| | in the mint for this item. | | |
| | | Time frame: pas | st 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | None | |
| 1 | Consulting fees | None | |
| | i Consuluie iees | I INDIE | i l |

| 5 | Payment or honoraria for | None | |
|-----|--|------------------------------|----------------|
| | lectures, presentations, speakers bureaus, | | |
| | | | |
| | manuscript writing or educational events | | |
| 6 | Payment for expert | None | |
| | testimony | | |
| | | | |
| 7 | Support for attending meetings and/or travel | None | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | None | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | None | |
| | Safety Monitoring Board or Advisory Board | | |
| 10 | Leadership or fiduciary role | None | |
| 10 | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | None | |
| | | | |
| 12 | Descipt of actions and | Nana | |
| 12 | Receipt of equipment, materials, drugs, medical | None | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | None | |
| | financial interests | | |
| | | | |
| Ple | ease summarize the above c | onflict of interest in the f | following box: |
| | None | | |
| | | | |

| None | | | |
|------|--|--|--|
| | | | |
| | | | |
| | | | |
| | | | |

as a

| Date | e:2021.10.9 | | |
|-------------------------|---|--|---|
| | r Name: Haitao M | | |
| Man | nuscript Title:Bioinf | ormatics analysis and ex | xperimental verification identifying FBXO45 gene as |
| | | nageal cancer): | |
| relate parte to trelate | ted to the content of your ies whose interests may be ansparency and does not tionship/activity/interest, | manuscript. "Related" me e affected by the content on necessarily indicate a bias. it is preferable that you do | I relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so. |
| | uscript only. | | · · · · · · · · · · · · · · · · · · · |
| to the med | ne epidemiology of hypert lication, even if that medic | ension, you should declare cation is not mentioned in t pport for the work reporte | defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. In this manuscript without time limit. For all other items, |
| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| | | Time frame: Since the initia | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| i | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | None | |
| 1 (| Consulting fees | None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | | |
|---|--|------|--|--|
| 6 | Payment for expert testimony | None | | |
| 7 | Support for attending meetings and/or travel | None | | |
| 8 | Patents planned, issued or pending | None | | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | | |
| | | | | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | | |
| 11 | Stock or stock options | None | | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | | |
| 13 | Other financial or non- financial interests | None | | |
| Please summarize the above conflict of interest in the following box: None | | | | |